Recent News

ASCO20: High Risk for Hospitalization for Patients With Thoracic Malignancies and COVID-19 Infection

ASCO20: ‘Extraordinary’ Results With Adjuvant Osimertinib in Early-Stage EGFR-Mutant NSCLC

FDA Approves Chemotherapy Plus Immunotherapy Combination in First-Line Treatment of Resistant NSCLC

Pulmonology Expert Panel Offers Guidance During the COVID-19 Pandemic

FDA Approves TKI Inhibitor Brigatinib for ALK-Positive Metastatic NSCLC

COVID-19 Pandemic–Related Challenges in Lung Cancer Therapy

FDA Approves Atezolizumab for Metastatic NSCLC With High PD-L1 Expression

Nivolumab/Ipilimumab Combination Receives FDA Approval in First-Line Treatment of Metastatic NSCLC

ASCO20 Preview: Study Finds Lung Cancer Survival Improved With Even Recent Smoking Cessation

DDW 2020: Risk of Lung Cancer in Patients With Inflammatory Bowel Disease

AACR 2020: Final IMpower150 Analysis of Chemoimmunotherapy in Nonsquamous Lung Cancer

Early Phase of Lung Pathology in COVID-19: Case Studies From China

FDA Approves Selpercatinib for RET Fusion–Positive NSCLC

Capmatinib Approved by FDA for Metastatic MET Exon 14–Mutated NSCLC

AACR 2020: MET Inhibitor Therapy in Lung Cancer With Brain Metastasis

Immunotherapy-Treated Patients With Lung Cancer: Beta-Blocker and Mortality Connection?

AACR 2020: Global Registry of Mortality in Patients With Lung Cancer and COVID-19

Pembrolizumab Receives FDA Accelerated Approval for Alternative Dosing Schedule

AACR 2020: Targeting EGFR Exon 20–Mutant Non–Small Cell Lung Cancer

Lung Cancer Treatment During the COVID-19 Pandemic: Balancing Risks and Benefits

The Need for COVID-19 Testing in Patients With Lung Cancer

ESTRO/ASTRO Recommendations on Lung Cancer Radiotherapy During COVID-19 Pandemic

COVID-19 Infection in a Patient on Immunotherapy for Lung Cancer Since 2013

FDA Grants Priority Review to Nivolumab/Ipilimumab in First-Line Treatment of Lung Cancer

Predicting Sensitivity to Therapy for NSCLC With Artificial Intelligence Model

First-Line Treatment of Metastatic Lung Cancer: Patient and Caregiver Preferences

Predicting Lung Cancer Response to Immunotherapy With Multimodal Genomic Features

Pembrolizumab Plus NK-Cell Therapy for Advanced Lung Cancer

Novel Assay Is Focus of Drug Screening Research in Resistant Lung Cancer

Bispecific Antibody Granted FDA Breakthrough Therapy Designation for Exon 20–Mutated NSCLC

Can Influenza Vaccines Trigger Immune Response in Patients With Lung Cancer?

FDA Accepts Biologics License Application for Proposed Biosimilar to Bevacizumab

Physical Activity and Quality of Life After Radiation Therapy for Lung Cancer

Brigatinib Granted FDA Priority Review for ALK-Positive Metastatic NSCLC

Atezolizumab Receives FDA Priority Review in NSCLC

ASCO-SITC 2020: HLA Expression in Primary Lung Tumors and Brain Metastases

MET Inhibitor Capmatinib Granted FDA Priority Review in Advanced Lung Cancer

ASCO–SITC 2020: Interim Trial Results With Pepinemab/Avelumab in Advanced NSCLC

ASCO-SITC 2020: Radiation Recall Pneumonitis and Nivolumab for Lung Cancer

Priority Review of Selpercatinib in RET-Driven Lung Cancer Granted by FDA

STS 2020: Intraoperative Molecular Imaging During Surgery for NSCLC

Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer

PET Imaging of Mitochondrial Activity in Lung Tumor Cells

FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer

Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?

ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer

RSNA 2019: Deep Learning Tool and Cardiovascular Health on Lung Cancer Screenings